Quidel Corporation (QDEL): Price and Financial Metrics
QDEL Price/Volume Stats
Current price | $48.26 | 52-week high | $98.67 |
Prev. close | $47.00 | 52-week low | $41.75 |
Day low | $46.92 | Volume | 703,200 |
Day high | $48.44 | Avg. volume | 1,028,850 |
50-day MA | $55.61 | Dividend yield | N/A |
200-day MA | $69.91 | Market Cap | 3.23B |
QDEL Stock Price Chart Interactive Chart >
QDEL POWR Grades
- QDEL scores best on the Value dimension, with a Value rank ahead of 93.42% of US stocks.
- The strongest trend for QDEL is in Value, which has been heading up over the past 26 weeks.
- QDEL's current lowest rank is in the Momentum metric (where it is better than 7.41% of US stocks).
QDEL Stock Summary
- QDEL's went public 31.86 years ago, making it older than 82.13% of listed US stocks we're tracking.
- With a price/earnings ratio of 367.5, QUIDELORTHO CORP P/E ratio is greater than that of about 98.48% of stocks in our set with positive earnings.
- In terms of twelve month growth in earnings before interest and taxes, QUIDELORTHO CORP is reporting a growth rate of -84.99%; that's higher than merely 15.84% of US stocks.
- If you're looking for stocks that are quantitatively similar to QUIDELORTHO CORP, a group of peers worth examining would be IAS, PCRX, PUBM, DBRG, and HLLY.
- Visit QDEL's SEC page to see the company's official filings. To visit the company's web site, go to www.quidel.com.
QDEL Valuation Summary
- QDEL's price/earnings ratio is 373.1; this is 1179.93% higher than that of the median Healthcare stock.
- QDEL's price/sales ratio has moved down 2.3 over the prior 243 months.
Below are key valuation metrics over time for QDEL.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
QDEL | 2023-12-29 | 1.6 | 1 | 373.1 | 44.5 |
QDEL | 2023-12-28 | 1.6 | 1 | 379.8 | 45.0 |
QDEL | 2023-12-27 | 1.6 | 1 | 381.9 | 45.2 |
QDEL | 2023-12-26 | 1.6 | 1 | 381.3 | 45.1 |
QDEL | 2023-12-22 | 1.6 | 1 | 374.5 | 44.6 |
QDEL | 2023-12-21 | 1.6 | 1 | 373.5 | 44.5 |
QDEL Growth Metrics
- The 4 year price growth rate now stands at 535.53%.
- Its 5 year net cashflow from operations growth rate is now at 232.27%.
- The 3 year price growth rate now stands at 69.63%.
The table below shows QDEL's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 3,266 | 885.3 | 548.7 |
2022-09-30 | 3,036.326 | 1,037.277 | 809.753 |
2022-06-30 | 2,762.262 | 1,124.036 | 1,006.305 |
2022-03-31 | 2,325.472 | 721.384 | 1,006.078 |
2021-12-31 | 1,698.551 | 805.869 | 704.226 |
2021-09-30 | 1,870.887 | 923.623 | 883.039 |
QDEL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- QDEL has a Quality Grade of B, ranking ahead of 85.03% of graded US stocks.
- QDEL's asset turnover comes in at 1.046 -- ranking 21st of 680 Pharmaceutical Products stocks.
- SYRS, ONVO, and SESN are the stocks whose asset turnover ratios are most correlated with QDEL.
The table below shows QDEL's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 1.046 | 0.813 | 1.894 |
2021-03-31 | 1.203 | 0.825 | 2.292 |
2020-12-31 | 1.314 | 0.812 | 2.053 |
2020-09-30 | 0.980 | 0.739 | 1.094 |
2020-06-30 | 0.705 | 0.663 | 0.537 |
2020-03-31 | 0.625 | 0.614 | 0.329 |
QDEL Price Target
For more insight on analysts targets of QDEL, see our QDEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $127.75 | Average Broker Recommendation | 1.8 (Moderate Buy) |
Quidel Corporation (QDEL) Company Bio
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
Latest QDEL News From Around the Web
Below are the latest news stories about QUIDELORTHO CORP that investors may wish to consider to help them evaluate QDEL as an investment opportunity.
Investors in QuidelOrtho (NASDAQ:QDEL) have unfortunately lost 59% over the last three yearsInvesting in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of... |
QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, December 22, 2023--QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced that Douglas Bryant, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco, CA, scheduled for 12:00 p.m. ET / 9:00 a.m. PT. |
QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR AssaySAN DIEGO, December 20, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received 510(K) clearance from the U.S. Food and Drug Administration for its innovative Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic test for the detection and differentiation of Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV |
Why is QuidelOrtho (QDEL) a Good Stock to Invest in?ClearBridge Investments, an investment management company, released its “ClearBridge All Cap Value Strategy” third quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy outperformed the benchmark, the Russell 3000 Value Index, in the third quarter. Favorable stock selection in the consumer discretionary, healthcare, and utilities sectors, as well as an […] |
QuidelOrtho to Participate in the Evercore ISI ConferenceSAN DIEGO, November 16, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Evercore ISI conference in Miami, FL, on November 30, 2023. |
QDEL Price Returns
1-mo | 3.12% |
3-mo | -34.52% |
6-mo | -33.93% |
1-year | -45.07% |
3-year | -60.82% |
5-year | -26.29% |
YTD | -34.52% |
2023 | -13.97% |
2022 | -36.54% |
2021 | -24.86% |
2020 | 139.44% |
2019 | 53.69% |
Continue Researching QDEL
Here are a few links from around the web to help you further your research on Quidel Corp's stock as an investment opportunity:Quidel Corp (QDEL) Stock Price | Nasdaq
Quidel Corp (QDEL) Stock Quote, History and News - Yahoo Finance
Quidel Corp (QDEL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...